Core--Protocol Specific Research Support

方案特定研究支持(PSRS)是一项努力，旨在扩大KCI由研究人员发起的临床试验的数量。必须提供支持以进行初步研究，其中大部分目前不是由NCI或其他机构资助的。PSRS的目的是提供一种行政支持机制，以提供数据管理、收集患者数据，并支持癌症中心内的创新临床试验。目标是促进研究人员发起的试验，将我们基础科学实验室的新结果带到临床和人口研究领域。授予一名研究人员PSR是根据科学领袖理事会的建议进行的。副中心主任、项目负责人或多学科团队负责人可以提名支持方案。建议将根据其科学价值和在癌症中心内开发新的研究途径的重要性进行评估。尽管所有建议都得到了认真考虑，但鼓励开展研究新途径和获得外部资金的潜力的研究。癌症中心内有许多由研究人员发起的翻译研究。这些包括新的和分子靶向治疗，以及功能成像技术。这些试验寻求测试新的靶向疗法，既作为单一药物， 并与更成熟的细胞毒疗法相结合。它们通常包括根据血液样本和肿瘤活检来衡量治疗效果。新的成像方法是这项工作不可或缺的一部分，因为它们提供了一种非侵入性的方法来测试这些治疗方法。在未来，我们计划支持I期、II期和成像/相关试验的混合。 请求为1.5FTE数据管理提供资金支持，以支持创新试验。数据管理将包括在登记参加试验之前确认患者的资格，从各种来源提取和整理数据，确保进行质量控制检查。

The Protocol-Specific Research Support (PSRS) is an effort to expand the number of investigator-initiated clinical trials at KCI. Support must be available to conduct preliminary studies, most of which are not presently funded by the NCI or other agencies. The purpose of the PSRS is to provide an administrative support mechanism to provide data management, collection of patient data, and to support innovative clinical trials within the Cancer Center. The objective is to foster investigator-initiated trials, which bring new results from our basic science laboratories to the clinical and population studies arenas. The awarding of PSRS to an investigator is done at the recommendation of the Scientific Leadersip Council. Associate center directors, Program leaders, or heads of the Multidisciplinary Teams can nominate protocols for support. Proposals are evaluated for their scientific merit and importance in developing new avenues of research within the Cancer Center. Although all proposals are given serious consideration, studies that show the potential to develop new avenues of research and secure external funding are encouraged. There are many investigator-initiated translational studies within the Cancer Center. These include novel and molecular targeted therapies, and functioning imaging techniques. These trials seek to test new, targeted therapies both as single agents, and in combination with more established cytotoxic therapy. They often include measurements of treatment effect based on blood samples and tumor biopsies. New imaging approaches are integral to this work as they provide a noninvasive way to test these treatment approaches. For the future, we plan to support a mixture of Phase I, Phase II, and imaging/correlative trials. Funding support for 1.5 FTE data management to support the innovative trials is requested. Data management will include confirming patient eligibility prior to registration to the trial, abstracting and collating data from various sources ensuring that qualtiy control checks are being conducted.